gliclazide / Generic mfg. - LARVOL DELTA

Rapid Deterioration of Glycaemic Control Revealing Interval Metastatic Pancreatic Cancer Despite a Recent Normal CT Scan. (PubMed, Cureus) - "We report the case of an 81-year-old woman with long-standing, type 2 diabetes, well-controlled on gliclazide, who developed worsening glycaemic control over four months...She presented with symptomatic hyperglycaemia with acutely deranged capillary blood sugar levels and a markedly elevated glycosylated haemoglobin (HbA1c), without evidence of infection or other precipitating factors. Repeat imaging demonstrated a necrotic pancreatic mass with metastatic disease and concurrent saddle pulmonary embolism. This case demonstrates that pancreatic malignancy may become apparent despite previously normal imaging and illustrates the diagnostic challenge when longstanding diabetes suddenly deteriorates."

Journal • Cardiovascular • Diabetes • Infectious Disease • Metabolic Disorders • Oncology • Pancreatic Cancer • Pancreatitis • Pulmonary Embolism • Respiratory Diseases • Solid Tumor • Type 2 Diabetes Mellitus

Method Development for Simultaneous Quantification of Anti-diabetic Drugs in Combined Solid Dosage Form: A Focus on Sulfonylureas, Biguanides, and Thiazolidinediones. (PubMed, Curr Drug Res Rev) - "Sulfonylureas and Biguanides, particularly Gliclazide, Glimepiride, Glipizide, Glibenclamide, and Metformin, are commonly used in combination therapies for improved glycemic control. RP-HPLC and MS-based techniques can enhance data processing efficiency. These advancements will strengthen pharmaceutical quality control, ensure the safety and efficacy of anti-diabetic drug formulations, while optimizing therapeutic outcomes for diabetes management."

Journal • Review • Diabetes • Metabolic Disorders

Improving diabetes management in older adults with cancer: a quality improvement project to enhance monitoring during steroid-based systemic anti-cancer therapy. (PubMed, Eur Geriatr Med) - "The GOLD pathway appears feasible, safe, and effective in managing SIH in older adults with cancer. Its success highlights the value of multidisciplinary collaboration and iterative refinement in addressing a critical gap in geriatric oncology care, as well as supporting structured diabetes monitoring in clinical practice. Larger multi-centre implementation effectiveness evaluation will enable sustainable, cost-effective practice across diverse settings."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Oncology

Initial treatment for uncontrolled type 2 diabetes: A clinical trial comparing basal insulin and modified-release gliclazide. (PubMed, Caspian J Intern Med) - "The patients were randomly assigned into one of two intervention groups: the Gliclazide-MR group (n=45), receiving 30 mg of modified-release gliclazide twice daily, or the Basal Insulin group (n=45), receiving basal insulin (detemir or glargine) at a dosage of 0.1--0.3 units per kilogram of body weight. Both basal insulin and modified-release gliclazide demonstrated efficacy in improving glycemic control in patients with severe hyperglycemia. The optimal treatment choice should be individualized based on patient-specific factors and treatment goals."

Journal • Diabetes • Endocrine Disorders • Metabolic Disorders • Type 2 Diabetes Mellitus

Sustainable stability-indicating spectra manipulations for the concurrent quantification of gliclazide and its impurity A as the possible alkaline degradation product: Multi-Color Analytical Profile Assessment. (PubMed, Sci Rep) - "Furthermore, the analytical strategy was comprehensively assessed using multi-dimensional tools, including RAPI and AMRI for analytical performance and reliability, CaFRI for carbon-footprint reduction, CACI for analytical practicality, and the RGB 12 model for an integrated multi-colored analytical profile. In summary, the developed methods provide a highly efficient, environmentally friendly, and analytical alternative to conventional chromatographic techniques for the routine quality control and green pharmaceutical analysis of gliclazide in bulk and dosage forms."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A rare case of gliclazide-induced symptomatic bradycardia in type 2 diabetes mellitus. (PubMed, JCEM Case Rep) - "After a modification in his antidiabetic treatment, the patient continued to exhibit no symptoms. This case underscores the necessity of identifying rare yet significant cardiac adverse effects associated with gliclazide, particularly in elderly patients, to facilitate prompt intervention and prevent unwarranted investigations."

Journal • Cardiovascular • Diabetes • Hypertension • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Sulfonylureas beyond diabetes: A comprehensive review on anticancer and off-target effects (1956-2025). (PubMed, Eur J Med Chem) - "Glibenclamide emerges primarily as a chemosensitizing and transporter-modulating compound, gliclazide as a drug with antioxidant, anti-inflammatory, and DNA-protective properties, glimepiride as a promising synergistic agent with additional AKR1C3-inhibitory activity, tolbutamide as a modulator of gap-junction signaling and mitochondrial stability, and chlorpropamide derivatives as ALDH-targeting chemosensitizers. At the same time, the review highlights major translational constraints, including weak baseline cytotoxicity for most SUs, frequent exposure mismatches between experimental and clinical settings, heterogeneous safety profiles, photoreactivity, and limited commercial incentives for development, while also outlining practical strategies to address these limitations. Overall, SUs should not be viewed as a single repurposing candidate, but as a chemically related set of drugs that require indication-specific and compound-specific selection for future oncology..."

Journal • Review • Diabetes • Metabolic Disorders • Oncology • Type 2 Diabetes Mellitus

Green Approach to Enhance Dissolution of Gliclazide: Thermoresponsive Solid Dispersion Based on Poloxamer 188/Propylene Glycol/Labrasol Ternary System. (PubMed, Pharmaceutics) - " The present thermoresponsive solid dispersion provides a green alternative to conventional solid dispersion techniques. It avoids reliance on organic solvents, processing that demands high energy input, and additional post-processing operations."

Journal • Gastrointestinal Disorder

Comparative thromboembolic risk and polypharmacy-related drug-drug interaction signals among antidiabetic medications: a large-scale FAERS pharmacovigilance study. (PubMed, Front Pharmacol) - "We analyzed 81,280,515 FAERS reports from 2004-2025, of which 498,750 (0.61%) involved at least one of 30 antidiabetic drugs, revealing strong arterial thromboembolic signals for rosiglitazone (IC = 4.68), gliclazide (IC = 1.55), linagliptin (IC = 1.56), dapagliflozin (IC = 1.25), and several DPP-4 inhibitors. Only insulin degludec (IC = 0.73, IC025 = 0.61) and insulin aspart (IC = 0.28, IC025 = 0.21) showed nominal venous thromboembolic signals...Moreover, 257 significant drug-drug interactions were identified, particularly between insulin analogues and simvastatin, acetaminophen, or gabapentin...Numerous significant drug-drug interactions were also detected, particularly for insulin analogues with other drugs. Further research is necessary to understand the clinical importance of these interactions."

Adverse events • Journal • Cardiovascular

The Impact of Polymers in Amorphous Solid Dispersion on the Bioavailability of Sulfonylureas and Meglitinides. (PubMed, Drug Des Devel Ther) - "Studies consistently show that ASD formulations of antidiabetic drugs such as glimepiride, repaglinide, gliclazide, gliquidone, and glyburide enhance insulin secretion and contribute to more effective glycemic control, showing the potential of ASD in improving the therapeutic performance of poorly soluble antidiabetic agents. By enhancing solubility, stability, and bioavailability, ASD technology holds significant promise for developing more potent and effective antidiabetic therapies, ultimately supporting better patient care and addressing the global burden of diabetes mellitus."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Tunable dissolution of poorly soluble gliclazide by surface coating via room-temperature atomic layer deposition. (PubMed, J Chem Phys) - "The results demonstrate the potential of SiO2 ALD not only in overcoming solubility-related limitations but also in providing a method of multipurpose design for controlled drug delivery. Given its compatibility with pharmaceutical manufacturing, our approach presents a promising pathway to enhance bioavailability and optimize the release kinetics of other poorly soluble drugs."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Biochemical and antidiabetic properties of Elaeocarpus angustifolius Blume: In vitro, In vivo, and In silico insights. (PubMed, PLoS One) - "Enzyme inhibition assays revealed methanol extract has strong α-glucosidase (IC₅₀ = 0.79 ± 0.13 µg/mL) and α-amylase (IC₅₀ = 3.48 ± 0.00 µg/mL) inhibitory effects, comparable to acarbose (IC₅₀ = 13.51 ± 0.22 µg/mL and IC₅₀ = 25.30 ± 0.85 µg/mL), respectively...The extract-treated group also showed higher hepatic glycogen content (14.06 ± 0.002 mg/mL) than the Gliclazide-treated group (12.82 ± 0.002 mg/mL). In silico molecular docking identified Corilagin exhibiting the highest binding affinity (-10.3 kcal/mol), stable interaction (RMSD = 1.469 ± 0.133 Å), and favorable binding free energy (ΔGBFE = -27.48 ± 3.15) with α-amylase, suggesting that it may act as a competitive inhibitor of an enzyme's active site. Overall, these findings highlight that E. angustifolius bark significantly inhibits glucose absorption and improves dyslipidemia to some extent, while in silico analysis suggests that Corilagin has..."

Journal • Preclinical • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus

RGD-Functionalized ZIF-8 Nanocarriers Enable Highly Selective Delivery of Repurposed Gliclazide in Breast Cancer. (PubMed, ACS Appl Bio Mater) - "Cytotoxicity evaluation at 48 h revealed that RGD@nZIF-8/GLI enhanced toxicity against MCF-7 breast cancer cells (44% at 1 μg mL-1) while maintaining reduced toxicity toward MRC-5 normal fibroblasts, resulting in a markedly improved selectivity index. Overall, this work demonstrates that RGD-functionalized nZIF-8 is a promising pH-responsive and selective nanoplatform for the targeted delivery of repurposed therapeutics in breast cancer treatment."

Journal • Breast Cancer • Oncology • Solid Tumor

Patterns and determinants of drug-drug interactions among community-dwelling older adults in Saudi Arabia: a cross-sectional study. (PubMed, Front Pharmacol) - "Amlodipine, aspirin, and insulin were the most commonly implicated medications, while atorvastatin, perindopril, and gliclazide were frequently involved in severe interactions. Although many interactions were classified as moderate or severe, most required monitoring rather than therapy modification, and their clinical relevance may vary depending on dosage and treatment context. Routine DDI screening and pharmacist-led medication review may enhance medication safety."

Journal • Observational data • Cardiovascular • Hypertension

Sustained Insulin Independence Following Lifestyle Intervention in a 78-Year-Old Patient With Long-Standing Type 2 Diabetes: A Six-Year Follow-Up Case Report. (PubMed, Cureus) - "At the 77-month follow-up, the patient maintained an insulin-free status on minimal oral therapy (gliclazide), with stable weight (63.5 kg) and HbA1c (6.6%). Fasting insulin (4.2 μU/mL) and C-peptide (1.36 ng/mL) levels confirmed preserved endogenous insulin secretion. This case illustrates that even elderly patients with very long-standing T2D may achieve sustained insulin withdrawal in the context of comprehensive ILI, underscoring the importance of integrating lifestyle medicine into diabetes care to reduce polypharmacy and enhance long-term outcomes."

Journal • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • CRP

Shark pedicle island flap for basal cell carcinoma of the perialar zone of the nose: photoxicity and photocarcinogenicity mediated by the intake of potentially nitrosamine contaminated drugs  -a possible new explanation for the skin cancers pathogenesis (EADV-Sp 2026) - "Results We inform about another polymedication intake in a patient with arterial hypertension and diabetes mellitus, which includes the following medications: gliclazide 60 mg once daily and metformin hydrochloride 850 mg once daily, both since 24 years ; sotalol hydrochloride 80 mg since 2 years; bisoprolol fumarate 5 mg since 17 years; candesartan cilexetil/hydrochlorothiazide 16 mg/ 12.5 mg since 2 years; and lercanidipine hydrochloride 20 mg also since 2 years. This article focuses on the possible role of drug-mediated photo nitrosogenesis/ carcinogenesis of skin cancer by briefly reviewing and analyzing the available literature to date. Figure 3: 1 month follow-up"

Basal Cell Carcinoma • Diabetes • Genetic Disorders • Metabolic Disorders • Non-melanoma Skin Cancer • Oncology • Pulmonary Arterial Hypertension • Skin Cancer

A near-infrared multifunctional fluorescent probe for simultaneous tracking of mitochondrial viscosity/polarity and ONOO. (PubMed, Talanta) - "Using this probe, we revealed for the first time that gliclazide and resveratrol alleviated diabetes by inhibiting oxidative stress related mitochondrial microenvironment deterioration. Furthermore, PEQ-Bf enabled in situ imaging of viscosity and polarity changes in diabetic and chronic wound-healing mouse models. Thus, PEQ-Bf offered a promising chemical tool for elucidating the role of mitochondrial microenvironment in disease progression."

Journal • Diabetes • Metabolic Disorders

Anti-diabetic potential of Artemisia monosperma Delile extract related to anti-inflammatory, antioxidant, and wound-healing properties. (PubMed, Sci Rep) - "The DAME exhibits potent antihyperglycemic activity, with a 300 mg% dose reducing blood glucose levels by approximately 26% in a Type 2 diabetes model, comparable to diamicron...monosperma DAME contains a variety of phenolic compounds and shows a potent multi-functional agent possessing anti-diabetic, anti-inflammatory, wound healing, and antioxidant activities, suggesting its therapeutic potential. However, more research is necessary to confirm its safety for clinical application."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • CRP • TNFA

The Implementation of a Clinical Decision Support System for Managing Drug-Disease Interactions in Outpatients with Cardiovascular and Diabetic Comorbidities: An Interventional Study at a Tertiary Hospital in Vietnam. (PubMed, Hosp Pharm) - "Notably, relative contraindications involving bisoprolol - chronic obstructive pulmonary diseases and gliclazide-hepatic fibrosis - cirrhosis sharply reduced post-intervention (P < 0.001). "Use with caution" interactions also witnessed a decline from 0.20% to 0.13% (P < 0.05), most significantly for lisinopril/hydrochlorothiazide - gout (P < 0.001)...The integration of CDSS into HIS and pharmacist interventions were associated with significantly reduced harmful DDSIs in high-risk CV-DM patients. This approach demonstrates the value of integrated clinical tools and multidisciplinary collaboration in optimizing medication safety in outpatient settings."

Journal • Cardiovascular • Chronic Obstructive Pulmonary Disease • Diabetes • Fibrosis • Gout • Hepatology • Immunology • Inflammatory Arthritis • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Rheumatology

Effect of intensive blood pressure and blood glucose control on cardiovascular outcomes driven by reductions in cardiovascular death and nephropathy: Win ratio analysis of ADVANCE Trial. (PubMed, Eur Heart J Cardiovasc Pharmacother) - P3 | "The win ratio approach confirms the robustness of the original ADVANCE findings while providing a more detailed understanding of the relative importance of individual outcomes. This method enhances the interpretation and communication of composite endpoint analyses."

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction • Renal Disease • Retinal Disorders

CT-L03-301: Clinical study to evaluate the efficacy and safety of Pioglitazone co-administration in patients with type II diabetes with insufficient glycemic control with Metformin and Empagliflozin combination therapy (clinicaltrialsregister.eu) - P2/3 | N=224 | Completed | Sponsor: Celltrion Inc. | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Blood Pressure Parameters and Risk of Cognitive Decline and Dementia in Type 2 Diabetes: Results From the ADVANCE Trial. (PubMed, J Am Heart Assoc) - P3 | "Higher BP variability and baseline PP, but not mean BP or BP load, were associated with higher odds of cognitive decline/dementia in patients with type 2 diabetes. BP variability and PP may be important therapeutic markers for the preservation of brain health."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Effects of Thickening Agents Used in Dysphagia on the In Vitro Dissolution of Gliclazide. (PubMed, Pharmacy (Basel)) - "Gliclazide dissolution was significantly delayed in the presence of Gloup® Forte across all media for both crushed and whole tablets, with f2 values below 50, indicating dissimilar profiles. Dissolution kinetics confirmed that mixing the formulated gliclazide with Gloup® Forte delayed the release and reduced the dissolution rate constant for drug from both crushed and whole gliclazide tablets in media studied."

Journal • Preclinical • Gastrointestinal Disorder

Acute Pancreatitis in a Young Patient With Type 2 Diabetes Mellitus Taking Sitagliptin and the Combined Oral Contraceptive Pill. (PubMed, Cureus) - "Sitagliptin was discontinued and replaced with gliclazide as opposed to metformin, which she was intolerant to. She demonstrated gradual improvement with normalization of inflammatory markers and triglyceride levels, achieving full recovery by day five. This case highlights the importance of considering sitagliptin and other medications, such as the combined oral contraceptive pill, as potential causes of acute pancreatitis and emphasizes the need for early recognition and prompt discontinuation of the offending agent to ensure optimal outcomes in patients."

Journal • Diabetes • Dyslipidemia • Gastroenterology • Hypertriglyceridemia • Inflammation • Metabolic Disorders • Pain • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus • CRP

Post Transplant Diabetes Mellitus and Type 2 Diabetes Mellitus – Are we treating them differently? (UKKW 2026) - "There was no significant difference in KTR with T2DM or PTDM prescribed gliclazide 45% vs 33%, respectively (p = 0.23), SGLT2 inhibitors 26% vs 15%, respectively (p = 0.21)...Discussion KTR with T2DM were more likely to receive insulin therapy and less likely to receive first-line metformin post transplantation than those with PTDM. For the former, kidney transplant may be an opportunity to review insulin and consider de-escalating therapy, especially within those with eGFR ≥ 30 ml/min/m². HbA1C was significantly better controlled in PTDM KTR than T2DM emphasizing the need for T2DM KTR to be reviewed and optimized following transplantation."

Post-transplantation • Cardiovascular • Diabetes • Metabolic Disorders • Transplantation • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus